Skip to main content

Table 2 Primary and secondary outcomes at days 7 and 14

From: Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial

Outcome/time

Treatment (n = 36)

Control (n = 36)

Absolute difference (95% CI)

Effect estimate (95% CI)

Abnormal chest X-ray, No. (%)

 Day 1

11 (31%)

9 (25%)

0.06

(−0.15 to 0.26)a

1.22

(0.58 to 2.59)c

 Day 14

12 (33%)

11 (31%)

0.03

(−0.19 to 0.24)a

1.09

(0.56 to 2.14)c

Positive PCR CT ratio, No. (%)

 Day 1

36 (100%)

36 (100%)

0.00

(0.00 to 0.00)a

1.00

(1.00 to 1.00)c

 Day 7

29 (81%)

30 (83%)

−0.03

(−0.21 to 0.15)a

0.97

(0.78 to 1.20)c

 Day 14

19 (53%)

20 (56%)

−0.03

(−0.26 to 0.20)a

0.95

(0.62 to 1.45)c

PCR CT ratio, Mean ± SD

 Day 1

23.65 ± 7.12

22.05 ± 5.10

1.60

(−1.31 to 4.51)b

  

 Day 7

25.99 ± 12.90

24.72 ± 11.17

1.27

(−4.48 to 7.03)b

  

 Day 14

17.43 ± 16.82

18.51 ± 17.34

−1.09

(−9.12 to 6.95)b

  

N gene, Mean ± SD

 Day 1

23.36 ± 6.20

22.42 ± 5.46

0.93

(−1.81 to 3.68)b

  

 Day 7

28.62 ± 11.10

26.22 ± 10.60

2.21

(−3.04 to 7.45)b

  

 Day 14

20.02 ± 17.29

19.17 ± 17.09

0.85

(−7.23 to 0.93)b

  
  1. aAbsolute difference is the difference in proportions
  2. bAbsolute difference is the mean difference
  3. cEffect estimate is the risk ratios (RR)